The goal of this clinical trial is to evaluate the efficacy and safety of transcranial direct current stimulation (tDCS) in reducing core symptoms of different psychiatric disorders using validated clinical scales. * To assess response and remission rates. * To evaluate the durability of treatment effects over follow-up. * To examine effects on cognition, daily functioning, and quality of life. * To monitor tolerability and adverse events.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
320
Preparation: * Clean scalp with alcohol to reduce impedance. * Apply conductive gel and position electrodes using the 10-20 EEG system. * Use rubber electrodes (5×7 cm) for anodal/cathodal placement. Stimulation: Ramp-up current over 30 sec to avoid discomfort. Monitor for adverse effects (tingling, itching, headache ). Post-Stimulation Assessment: * Evaluate symptom changes using standardized scales (e.g., HAM-D for depression, Y-BOCS for OCD). * Repeat sessions 3-5 times per week.. Safety and Monitoring Adverse Effects: Mild skin irritation, headache (rarely seizures-screen high-risk patients(. Contraindications: Metallic implants, scalp lesions, epilepsy history. Conclusion tDCS is a promising neuromodulatory tool for psychiatric disorders, with varying protocols based on disorder-specific neural targets.
Faculty of Medicine
Cairo, Menofia, Egypt
Montgomery-Åsberg Depression Rating Scale
Depression severity was assessed using the Montgomery-Åsberg Depression Rating Scale. The total scores on this scale range from a minimum of 0 to a maximum of 60, with higher scores indicating a greater severity of depressive symptoms (a worse outcome)
Time frame: The assessment period for each participant was 24 weeks from the start of their participation in the study.
Positive and Negative Syndrome Scale
Symptom severity was evaluated using the Positive and Negative Syndrome Scale. Total scores on this scale range from a minimum of 30 to a maximum of 210, with higher scores indicating a greater severity of symptoms (a worse outcome).
Time frame: The assessment period for each participant was 24 weeks from the start of their participation in the study.
Yale-Brown Obsessive Compulsive Scale
The severity of obsessive-compulsive symptoms was measured using the Yale-Brown Obsessive Compulsive Scale. Total scores on this scale range from a minimum of 0 to a maximum of 40, with higher scores indicating more severe symptoms (a worse outcome).
Time frame: The assessment period for each participant was 24 weeks from the start of their participation in the study.
Generalized Anxiety Disorder-7
Anxiety severity was measured using the Generalized Anxiety Disorder-7 scale. Total scores on this scale range from a minimum of 0 to a maximum of 21, with higher scores indicating more severe anxiety symptoms (a worse outcome).
Time frame: The assessment period for each participant was 24 weeks from the start of their participation in the study.
Insomnia Severity Index - 7 items
The severity of insomnia was assessed using the Insomnia Severity Index. Total scores on this scale range from a minimum of 0 to a maximum of 28, with higher scores indicating more severe insomnia symptoms (a worse outcome).
Time frame: The assessment period for each participant was 24 weeks from the start of their participation in the study.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.